Process Development and Manufacturing Services Agreement by and between Proteon Therapeutics and Lonza LtdProcess Development and Manufacturing Services Agreement • September 16th, 2014 • Proteon Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledSeptember 16th, 2014 Company Industry JurisdictionThis Process Development and Manufacturing Services Agreement (this “Agreement”) is effective as of September 1, 2009 (the “Effective Date”), by and between Proteon Therapeutics, a Delaware corporation, with an address at 200 West Street, Waltham, Massachusetts (“PROTEON”), and Lonza Ltd, a Swiss company with an address at Muenchensteinerstrasse 38, CH-4002 Basel, Switzerland (“LONZA”) (each, a “Party” and together the “Parties”).
Process Development and Manufacturing Services Agreement by and between Proteon Therapeutics and Lonza LtdProcess Development and Manufacturing Services Agreement • August 26th, 2014 • Proteon Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledAugust 26th, 2014 Company Industry JurisdictionThis Process Development and Manufacturing Services Agreement (this “Agreement”) is effective as of September 1, 2009 (the “Effective Date”), by and between Proteon Therapeutics, a Delaware corporation, with an address at 200 West Street, Waltham, Massachusetts (“PROTEON”), and Lonza Ltd, a Swiss company with an address at Muenchensteinerstrasse 38, CH-4002 Basel, Switzerland (“LONZA”) (each, a “Party” and together the “Parties”).
Process Development and Manufacturing Services Agreement by and between Proteon Therapeutics and Lonza LtdProcess Development and Manufacturing Services Agreement • June 25th, 2014 • Proteon Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledJune 25th, 2014 Company Industry JurisdictionThis Process Development and Manufacturing Services Agreement (this “Agreement”) is effective as of September 1, 2009 (the “Effective Date”), by and between Proteon Therapeutics, a Delaware corporation, with an address at 200 West Street, Waltham, Massachusetts (“PROTEON”), and Lonza Ltd, a Swiss company with an address at Muenchensteinerstrasse 38, CH-4002 Basel, Switzerland (“LONZA”) (each, a “Party” and together the “Parties”).